Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.2600
- TODAY'S CHANGE (%)-0.0400 (-0.7547%)
- Bid / Lots5.2400/ 1
- Ask / Lots5.2500/ 4
- Open / Previous Close5.3500 / 5.3000
- Day Range
- 52 Week Range
- Volume219,991
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 6801 | 5.345 |
| 09:34 ET | 5581 | 5.28 |
| 09:36 ET | 1071 | 5.31 |
| 09:38 ET | 10294 | 5.31 |
| 09:41 ET | 2000 | 5.3221 |
| 09:43 ET | 450 | 5.305 |
| 09:45 ET | 7138 | 5.26 |
| 09:48 ET | 5256 | 5.2799 |
| 09:50 ET | 2361 | 5.2785 |
| 09:52 ET | 400 | 5.31 |
| 09:54 ET | 1231 | 5.3161 |
| 09:57 ET | 100 | 5.29 |
| 09:59 ET | 100 | 5.29 |
| 10:01 ET | 100 | 5.3 |
| 10:03 ET | 600 | 5.3 |
| 10:10 ET | 11233 | 5.31 |
| 10:12 ET | 1837 | 5.31 |
| 10:14 ET | 2000 | 5.3 |
| 10:15 ET | 400 | 5.3 |
| 10:17 ET | 100 | 5.29 |
| 10:19 ET | 1924 | 5.3 |
| 10:21 ET | 730 | 5.2801 |
| 10:24 ET | 800 | 5.3 |
| 10:28 ET | 800 | 5.2795 |
| 10:30 ET | 3784 | 5.27 |
| 10:32 ET | 700 | 5.26 |
| 10:33 ET | 100 | 5.27 |
| 10:39 ET | 100 | 5.29 |
| 10:42 ET | 1200 | 5.26 |
| 10:44 ET | 5098 | 5.215 |
| 10:46 ET | 4400 | 5.24 |
| 10:48 ET | 300 | 5.245 |
| 10:50 ET | 100 | 5.25 |
| 10:51 ET | 212 | 5.26 |
| 10:53 ET | 813 | 5.259 |
| 10:57 ET | 200 | 5.26 |
| 11:00 ET | 6325 | 5.25 |
| 11:02 ET | 1224 | 5.24 |
| 11:06 ET | 250 | 5.2307 |
| 11:08 ET | 380 | 5.24 |
| 11:09 ET | 464 | 5.23 |
| 11:11 ET | 125 | 5.24 |
| 11:13 ET | 500 | 5.21 |
| 11:15 ET | 17916 | 5.22 |
| 11:18 ET | 1140 | 5.24 |
| 11:24 ET | 941 | 5.25 |
| 11:26 ET | 300 | 5.26 |
| 11:27 ET | 1999 | 5.24 |
| 11:29 ET | 1100 | 5.23 |
| 11:31 ET | 100 | 5.23 |
| 11:36 ET | 300 | 5.2329 |
| 11:38 ET | 216 | 5.24 |
| 11:42 ET | 1033 | 5.25 |
| 11:44 ET | 5995 | 5.26 |
| 11:45 ET | 500 | 5.26 |
| 11:47 ET | 289 | 5.26 |
| 11:49 ET | 750 | 5.26 |
| 11:51 ET | 11543 | 5.26 |
| 11:54 ET | 3298 | 5.26 |
| 11:56 ET | 1800 | 5.26 |
| 11:58 ET | 200 | 5.26 |
| 12:02 ET | 300 | 5.26 |
| 12:03 ET | 3700 | 5.25 |
| 12:05 ET | 100 | 5.26 |
| 12:09 ET | 2039 | 5.255 |
| 12:14 ET | 100 | 5.255 |
| 12:16 ET | 500 | 5.255 |
| 12:18 ET | 3646 | 5.26 |
| 12:20 ET | 200 | 5.26 |
| 12:23 ET | 200 | 5.26 |
| 12:25 ET | 8678 | 5.27 |
| 12:27 ET | 2275 | 5.29 |
| 12:30 ET | 2207 | 5.27 |
| 12:32 ET | 200 | 5.27 |
| 12:34 ET | 900 | 5.27 |
| 12:36 ET | 5428 | 5.31 |
| 12:38 ET | 5389 | 5.3 |
| 12:39 ET | 3940 | 5.31 |
| 12:41 ET | 1397 | 5.29 |
| 12:43 ET | 582 | 5.28 |
| 12:45 ET | 200 | 5.29 |
| 12:48 ET | 514 | 5.28 |
| 12:50 ET | 1700 | 5.27 |
| 12:52 ET | 182 | 5.26 |
| 12:54 ET | 200 | 5.26 |
Today
Sep 5, 2024
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26(th) Annual Global Investment Conference, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 314.9M | -8.2x | --- |
Inozyme Pharma Inc | 315.6M | -3.5x | --- |
Lyell Immunopharma Inc | 314.9M | -1.5x | --- |
Korro Bio Inc | 306.7M | -1.0x | --- |
GH Research PLC | 328.8M | 0.0x | --- |
Corvus Pharmaceuticals Inc | 330.3M | -11.8x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Principal Financial Officer and Principal Accounting Officer
- Michael Alfieri
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $314.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
